Next, we conducted an analysis of CNA events associated with KIFC2, and found that 52.5%, 49.8%, and 43.3% of patients with HR+/HER2– BC had some form of KIFC2 amplification (combined low-level and high-level) in the FUSCC, TCGA, and METABRIC data sets, respectively (Figure 1D). The gene discussed is ERBB2; the disease is breast cancer.